Thursday, September 24Thursday, 24 September 2026 - EST (Eastern Time, UTC-05:00

• RNA-based therapeutics and other advanced modalities are often limited by rapid hepatic uptake and clearance, reducing systemic bioavailability, restricting delivery beyond the liver, and contributing to liver-associated toxicity. These delivery barriers can constrain dose, efficacy, and therapeutic window.
• Nanobiotix’s Nanoprimer is a biocompatible, engineered liposome platform designed to transiently occupy cells of the mononuclear phagocyte system involved in hepatic clearance. Administered shortly before the therapeutic agent, Nanoprimer is designed to reduce liver elimination during the agent’s critical window of activity, increasing systemic exposure and improving the opportunity for target-tissue delivery.
• Multiple preclinical proof-of-concept studies have been demonstrated across modalities, including nucleic acid-LNPs, liposomes, oncolytic viruses, and recombinant proteins. By decreasing liver clearance, Nanoprimer has shown the potential to enhance efficacy, improve extrahepatic exposure, and reduce hepatotoxicity for therapies whose performance is limited by rapid hepatic uptake.

For years, Samyang Biopharm has successfully commercialized surgical sutures and modified anti-cancer generics based on its biodegradable polymers and polymeric-micelle formulation technology. Selectivity Enabling NanoShell (SENS™), is Samyang’s latest innovative lipid- biodegradable polymer hybrid technology optimized for tissue-selective delivery of nucleic acid therapeutics. SENS™ platform includes formulations targeting lung, muscle, liver, CNS, etc. tissues and specific cell types, including epithelial, endothelial, tumor, hepatocytes and neurons.

NanoReady SENS™ formulation is characterized by high splenic DC cell selectivity and its ready-to-use format. As a pre-made nanoparticle system, it can simply be combined with mRNA molecule before use in patient, which allows to streamline process development, reduce time-to-patient, and enable development of personalized cancer vaccines.

By pursuing active collaborations with global partners, Samyang is expanding SENS™ platform applications to various nucleic acid-based therapeutics, including cancer vaccines, gene therapies, tissue-specific gene regulation, gene editing, protein replacement, and more.

Traditional RNA drug development relies on costly trial-and-error design, often treating biological complexities as isolated problems. Therna Bio is redefining this paradigm through RNA-Logix™, an AI-native platform powered by our proprietary AI RNA Biologist. Built on one of the industry’s largest dataset of whole-system biological measurements generated in-house, our recursive AI models evaluate full RNA structures simultaneously rather than piece by piece. This enables Therna to address both sides of the RNA spectrum: designing synthetic mRNA therapeutics with enhanced stability, cell specificity, and protein expression, as well as optimizing oligonucleotides (ASO/siRNA) to precisely silence, edit, or activate target genes. By accelerating discovery from years to months at a fraction of traditional costs, Therna’s end-to-end engine converts complex RNA biology into scalable, high-value clinical opportunities and strategic partnerships.

Zipcode Bio was built on a simple premise: solving delivery to a new tissue doesn't yield one drug, it yields a portfolio. Founded with Nobel laureate Drew Weissman and a delivery team out of BioNTech, the company pairs AI-driven RNA and LNP design — two Nature Machine Intelligence papers to date — with a cutting-edge nanoparticle platform now reaching five organs. Co-founder and CEO Jason Zhang will show how programs in oncology, in vivo CAR-T, and immune aging emerged directly from delivery findings — and where the platform is open to partnership

An open Q&A session offering attendees the opportunity to engage directly with leading investors, gain insights into funding strategies, market trends, and what drives investment decisions in the RNA therapeutics space.